BioTuesdays

Tag - Naz Rahman

Clarus-Therapeutics
Markets

Maxim starts Clarus Therapeutics at buy; PT $13

Maxim Group initiated coverage of Clarus Therapeutics (NASDAQ:CRXT) with a “buy” rating and $13 price target. The stock closed at $5.61 on Sept. 28. Clarus is a commercial-stage company marketing Jatenzo, an oral...

September 29, 2021
180-Life-Sciences
Markets

Maxim starts 180 Life Sciences at buy; PT $11

Maxim Group initiated coverage of 180 Life Sciences (NASDAQ:ATNF) with a “buy” rating and $11 price target. The stock closed at $5.67 on Sept. 14. 180 Life Sciences is developing anti-inflammatory products with three...

September 15, 2021
Palisade Bio Logo
Markets

Maxim starts Palisade Bio at buy; PT $7

Maxim Group initiated coverage of Palisade Bio (NASDAQ:PALI) with a “buy” rating and price target of $7. The stock closed at $2.73 on Aug. 30. Palisade Bio is a clinical-stage company developing LB1148, an oral...

August 31, 2021